Présentation
Constitutive activity of the PI3K-Akt pathway is often associated with resistance to cancer therapies. Importantly PP2A1 is the Akt phosphatase that can inactivate this survival pathway associated with cancer progression. In this regard in collaboration with JH Colle (Institut Pasteur) we recently identified and patented cellular and viral penetrating sequences that activate PP2A1 to down-regulate PI3K-Akt-dependent survival of human radio-resistant glioblastoma cell lines. This work will be ended by in vivo proof of concept based on Tumor regression analysis (ongoing).